Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willingness to provide informed consent to participation in the study~  * Male or female 18-65 years of age~ * Peripheral blood microfilaremia levels \>50 microfilaria/ml (treatment group 1)~ * No evidence of filarial infection by Mf and Circulating filarial antigen (CFA) testing (treatment group 2)~ * No history of taking anti-filarial medications in past 2 years~Exclusion Criteria:~Known chronic illness, e.g. tuberculosis, diabetes, renal insufficiency~* Anemia (Hb \<7 g/dl) by HemaCue~* Not willing or able to give informed consent for the study~* Onchocerciasis rapid test (Ov16) and/or skin snip positive for onchocerciasis~* Permanent disability that prevents or impedes study participation and/or comprehension Pregnancy. Women will be tested with a rapid urine test for beta human chorionic gonadotropin (β-HCG)~* Biochemical abnormalities as indicated by liver function tests, and/or creatinine \>1.5 times above upper limit of the normal range.~* Receiving any routine medications that may interfere with test drug metabolism that cannot be stopped one week prior to onset of study~* Evidence of urinary tract infection as indicated by an active urinary sediment (\>6- 8 pus/neutrophil cells per field) or 3+ nitrate on dipstick. Individuals without a gross active sediment 1 or 2 plus nitrate or with 1 + protein will not be excluded. Similarly individuals with 1+ haemoglobin on dipstick or trace amount of blood in the will not be excluded.~* Lactose and/or gluten intolerance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Single IDA dose W. bancrofti positive (Type: ACTIVE_COMPARATOR): Single oral dose of Ivermectin, Diethylcarbamazine Albendazole (IDA) W. bancrofti infections positive
- Single IDA dose W. bancrofti negative (Type: ACTIVE_COMPARATOR): Single oral dose of Ivermectin, Diethylcarbamazine Albendazole (IDA) in 40 individuals who are free of W. bancrofti infection.

Based on this trial design, predict the completion outcome and termination type (if applicable).